Novo Nordisk : NVO

All Novo Nordisk Articles

180 Articles

Joel South | Jul 7, 2026 at 8:30 AM EDT

2 Dirt Cheap Healthcare Stocks to Buy in July

Healthcare has become Wall Street’s bargain bin in 2026, and value hunters are starting to pay attention. Drug pricing reform,…

Omor Ibne Ehsan | Jul 6, 2026 at 3:15 PM EDT

The Anti-Magnificent Seven Trade? VGK Is Quietly Creeping Toward Record Highs

European stocks are having their loudest year in a decade, and the Vanguard FTSE Europe ETF (NYSEARCA:VGK) is the vehicle…

Rich Duprey | Jun 30, 2026 at 9:38 AM EDT

AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology…

Alex Sirois | Jun 23, 2026 at 1:55 PM EDT

Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait

Everyone is still arguing about Novo Nordisk (NYSE:NVO | NVO Price Prediction), the Danish obesity juggernaut whose GLP-1 franchise turned…

Joel South | Jun 17, 2026 at 3:20 PM EDT

3 Beaten-Down Stocks That Could Roar Back in June

June is shaping up as a stock-picker’s month. Spring volatility has settled, and contrarian investors are scanning the wreckage for…

Joel South | Jun 13, 2026 at 9:30 AM EDT

3 Ridiculously Cheap Healthcare Stocks to Buy in June

Healthcare has spent 2026 on the sidelines while the rest of the market does the heavy lifting. The Health Care…

Vandita Jadeja | Jun 11, 2026 at 2:58 PM EDT

Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy

Eli Lilly (NYSE: LLY | LLY Price Prediction) and Novo Nordisk (NYSE: NVO) reported Q1 2026 results that pulled the…

Jeremy Phillips | Jun 11, 2026 at 9:30 AM EDT

The GLP-1 stock nobody is pricing in isn’t a drugmaker

Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food…

Gerelyn Terzo | Jun 3, 2026 at 9:03 AM EDT

Live Nasdaq Composite: Markets Take a Breather amid Stellar AI Earnings Cycle

This article will be updated throughout the day, so check back often for more daily updates. The markets are cradling…

Jeremy Phillips | Jun 3, 2026 at 8:38 AM EDT

5 Stocks Set to Cash in on The Next 90-Million Customer Industry. (It’s Not AI)

Wells Fargo’s chief agriculture economist Dr. Michael Swanson told Bloomberg Businessweek on May 29 that GLP-1 weight-loss drugs (Ozempic, Wegovy,…

Trey Thoelcke | May 26, 2026 at 8:50 AM EDT

If Viking Therapeutics Is Acquired, Here’s Who Wins

Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX | VKTX…

Vandita Jadeja | May 21, 2026 at 8:25 AM EDT

Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

Eli Lilly (NYSE:LLY | LLY Price Prediction) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5%…

Alex Sirois | May 18, 2026 at 1:55 PM EDT

Three Biotechs That Are Top Takeover Targets

Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious:…

David Moadel | May 5, 2026 at 10:44 AM EDT

Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show

Eli Lilly (NYSE:LLY | LLY Price Prediction) received another bullish call from Wall Street. Barclays analyst Emily Field raised her…

Thomas Richmond | Apr 30, 2026 at 8:05 PM EDT

Fast Money Panel Says Novo Nordisk Now More Compelling Than Eli Lilly After Falling 70%

CNBC’s Fast Money panel recently made a notable pivot on its April 24 episode, arguing that Novo Nordisk (NYSE:NVO |…

1 2 3 4 … 12

Novo Nordisk : NVO

All Novo Nordisk Articles

2 Dirt Cheap Healthcare Stocks to Buy in July

The Anti-Magnificent Seven Trade? VGK Is Quietly Creeping Toward Record Highs

AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait

3 Beaten-Down Stocks That Could Roar Back in June

3 Ridiculously Cheap Healthcare Stocks to Buy in June

Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy

The GLP-1 stock nobody is pricing in isn’t a drugmaker

Live Nasdaq Composite: Markets Take a Breather amid Stellar AI Earnings Cycle

5 Stocks Set to Cash in on The Next 90-Million Customer Industry. (It’s Not AI)

If Viking Therapeutics Is Acquired, Here’s Who Wins

Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

Three Biotechs That Are Top Takeover Targets

Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show

Fast Money Panel Says Novo Nordisk Now More Compelling Than Eli Lilly After Falling 70%

Gates-Backed Cascade Sees Opportunity in Republic Services That Half of Wall Street Misses

TotalEnergies CEO Just Exposed the $10 Secret That Makes the Hormuz Oil Panic Look Overblown

Where Canon Can Actually Disrupt ASML

Retired Lineman Makes Big Error With $310,000 Lump-Sum Pension Buyout

Trump Says $465,000 Makes You "Rich" In Retirement. Here's How Much Americans Say It Takes To Be Comfortable In Retirement.

Gates-Backed Cascade Sees Opportunity in Republic Services That Half of Wall Street Misses

TotalEnergies CEO Just Exposed the $10 Secret That Makes the Hormuz Oil Panic Look Overblown

Novo Nordisk : NVO

All Novo Nordisk Articles

2 Dirt Cheap Healthcare Stocks to Buy in July

The Anti-Magnificent Seven Trade? VGK Is Quietly Creeping Toward Record Highs

AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait

3 Beaten-Down Stocks That Could Roar Back in June

3 Ridiculously Cheap Healthcare Stocks to Buy in June

Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy

The GLP-1 stock nobody is pricing in isn’t a drugmaker

Live Nasdaq Composite: Markets Take a Breather amid Stellar AI Earnings Cycle

5 Stocks Set to Cash in on The Next 90-Million Customer Industry. (It’s Not AI)

If Viking Therapeutics Is Acquired, Here’s Who Wins

Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

Three Biotechs That Are Top Takeover Targets

Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show

Fast Money Panel Says Novo Nordisk Now More Compelling Than Eli Lilly After Falling 70%

Gates-Backed Cascade Sees Opportunity in Republic Services That Half of Wall Street Misses

TotalEnergies CEO Just Exposed the $10 Secret That Makes the Hormuz Oil Panic Look Overblown

Where Canon Can Actually Disrupt ASML

Featured Reads

Retired Lineman Makes Big Error With $310,000 Lump-Sum Pension Buyout

Trump Says $465,000 Makes You "Rich" In Retirement. Here's How Much Americans Say It Takes To Be Comfortable In Retirement.